- Oops!Something went wrong.Please try again later.
The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies.
But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ: EDIT), and high patient compliance remains.
Although early data suggest that lead asset NTLA-2001 can have a competitive profile in ATTR, penetration will be challenged due to alternative approved/investigational treatments characterized by favorable outcomes and high patient adherence.
BMO writes that IND approval for NTLA-2001 can drive ~10-15%+ upside in NTLA.
Price Action: NTLA shares are up 4.17% at $43.17 during the market session on the last check Friday.
Latest Ratings for NTLA
Initiates Coverage On
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.